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Abstract
Purpose Various studies in placental tissue suggest that
diabetes mellitus alters the expression of glucose transporter
(GLUT) proteins, with insulin therapy being a possible
modulatory factor. The aim of the present study was
quantitative evaluation of the expression of glucose trans-
porters (GLUT-1, GLUT-4, GLUT-9) in the placenta of
women in both, uncomplicated and diabetic pregnancy.
Additionally, the effect of insulin therapy on the expression
of selected glucose transporter isoforms was analyzed.
Methods Term placental samples were obtained from
healthy control (n= 25) and diabetic pregnancies, including
diet-controlled gestational diabetes mellitus (GDMG1) (n=
16), insulin-controlled gestational diabetes mellitus
(GDMG2) (n= 6), and pre-gestational diabetes mellitus
(PGDM) (n= 6). Computer-assisted quantitative morpho-
metry of stained placental sections was performed to
determine the expression of selected glucose transporter
proteins.
Results Morphometric analysis revealed a signiﬁcant
increase in the expression of GLUT-4 and GLUT-9 in
insulin-dependent diabetic women (GDMG2 + PGDM) as
compared to both, control and GDMG1 groups (p< .05).
Signiﬁcantly increased GLUT-1 expression was observed
only in placental specimens from patients with PGDM
(p< .05). No statistically signiﬁcant differences in GLUT
expression were found between GDMG1 patients and
healthy controls.
Conclusions The results of the study conﬁrmed the pre-
sence of GLUT-1, GLUT-4 and GLUT-9 proteins in the
trophoblast from both, uncomplicated and diabetic preg-
nancies. In addition, insulin therapy may increase placental
expression of GLUT-4 and GLUT-9, and partially GLUT-1,
in women with GDMG2/PGDM.
Keywords Glucose transporter ● Placenta ● Gestational
diabetes mellitus ● Pre-gestational diabetes mellitus ●
Quantitative morphometry
Introduction
In the course of pregnancy, transplacental nutrient transport
of amino acids, lipids, and carbohydrates designed to meet
the demands of the growing fetus constitutes the pre-
requisite condition of proper fetal development. Glucose,
belonging to the last group, is the principal energy substrate
for the fetus, the majority of which is supplied from the
maternal circulation. Besides the difference in glucose
concentration gradients in the maternal and fetal circulation,
the intensity of placental metabolism and blood ﬂow, the
expression and activity of speciﬁc transporters is one of the
key elements, which determine the ability of the human
placenta to transfer glucose. As a consequence, for nearly
three decades, transporter-dependent glucose ﬂux across the
placenta has been the subject of numerous studies, aiming
to evaluate the expression of selected transporter isoforms
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and its effect on maternal-fetal glucose exchange [1–9].
Particular attention has been paid to changes in the
expression and activity of glucose transporters in diabetic
pregnancy, where disturbances in transplacental energy
substrate supply may constitute one of the pathogenetic
mechanisms leading to fetal overgrowth [10].
Members of the facilitative glucose transporter (GLUT)
family vary in terms of substrate speciﬁcity, kinetics,
localization and expression in human tissues, and are
responsible for sodium-independent and concentration
gradient-compliant hexose transfer [11, 12]. In terms of
structure, all GLUT proteins encoded by the SLC2A gene
family consist of ~500 amino acids and comprise 12
transmembrane domains connected by hydrophilic loops
with both N and C termini localized in the cytoplasm [11–
13]. Out of the identiﬁed 14 transporter isoforms, three
(GLUT-1, GLUT-4 and GLUT-9) seem to be of particular
importance for placental glucose exchange. GLUT-1, which
is present in the majority of human tissues and, as a result, is
considered to be a constitutive transporter isoform, in the
placenta is found in the endothelial cells of placental villi,
cyto and syncytiotrophoblast, at the same time being the
primary transporter responsible for glucose transfer [1–5].
The characteristic for GLUT-4 close dependency on insulin
stimulation results in an important role of the transporter in
maintaining whole-body glucose homeostasis, whose pre-
sence was demonstrated together with insulin receptors in
stromal cells of the placental villi [7]. The last of the
transporters, GLUT-9, is the least known among all of the
above mentioned isoforms, capable of glucose and fructose
transfer, with positive expression in the placental syncytium
and vascular endothelium [8, 9].
Both, gestational diabetes mellitus (GDM) and pre-
gestational diabetes mellitus (PGDM) have been demon-
strated to contribute to changes in the expression and
activity of glucose transporters in the placenta, with insulin
therapy as a possible modulatory factor [8, 14–17]. It has
been speculated that increased glucose ﬂux into the fetal
circulation, followed by fetal hyperinsulinemia, increased
production of the growth factors, and ﬁnally macrosomia,
may be the consequences of these changes [14, 18]. The
hypothesis, however, needs to be veriﬁed, taking into
account the fact that the vast majority of the literature
reports have been small sample-size or have focused on the
expression of individual isoforms, mainly GLUT-1. More-
over, analysis of transporter expression only in membrane
fractions of the trophoblast in the studies conducted so far
may not have fully reﬂected the changes in the diabetic
placenta taking into account intracellular localization of
some GLUT isoforms, e.g. GLUT-4 or GLUT-1 [19, 20].
The aim of the present study was quantitative evaluation
of the expression of GLUT-1, GLUT-4 and GLUT-9 glu-
cose transporters in the placenta of women in both, healthy
pregnancy and pregnancy complicated by GDM/PGDM.
Additionally, the effect of insulin therapy on the expression




The placental samples were obtained from 53 women after
vaginal or cesarean delivery at the Department of Obste-
trics, Gynecology and Oncology, II Faculty of Medicine,
Medical University of Warsaw. Local Ethics Committee
approved of the study and all participants signed their
written informed consent (reference no. KB/150/2013). The
inclusion criteria were as follows: maternal age >18, sin-
gleton pregnancy, and gestational age of >37 weeks. Fetal
malformations, intrauterine fetal growth restriction, mater-
nal chronic or pregnancy-induced hypertension, chronic
renal or hepatic disease, in vitro fertilization, premature
rupture of membranes, and smoking constituted the exclu-
sion criteria.
The patients were divided into two groups: (i) study
group comprising women with GDM or PGDM, and
(ii) age-matched control group comprising women in an
uncomplicated pregnancy. GDM was diagnosed based on
the 75 g oral glucose tolerance test (OGTT) performed
between 24 and 28 gestational weeks, in accordance with
the criteria deﬁned by the Hyperglycemia and Adverse
Pregnancy Outcome study [21]. GDM patients received
dietary advice at the initial stage and insulin therapy was
introduced only in case of repeatedly inadequate glycemic
control (fasting blood glucose level >90 mg/dl and/or 1-h
postprandial blood glucose level >120 mg/dl). PGDM
patients received insulin over the entire course of preg-
nancy. In the periconceptional period, all PGDM women
remained under the care of the Diabetes Outpatient Clinic
and only patients with good glycemic control, whose con-
centration of glycated hemoglobin within the 3 month
period before pregnancy did not exceed 6%, were included.
PGDM patients with preexisting medical conditions
including cardiovascular diseases, nephro and retinopathy
were excluded from the study.
Diabetic patients were classiﬁed according to the White’s
Classiﬁcation as White class A, gestational diabetes con-
trolled with diet alone (GDMG1) or diet and insulin
(GDMG2), White class B, pre-gestational diabetes mellitus
with the onset at the age of ≥20, and White class C, PGDM
with the onset at the age of 10–19. All patients from the
study group were followed-up in the out-patient hospital
clinic until 38 weeks of gestation.
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Placental tissue collection and immunohistochemical
staining
Two separate cross-section specimens from the central and
the peripheral region of the placenta were collected imme-
diately upon vaginal delivery/cesarean section, ﬁxed in a
10% buffered formalin and embedded in parafﬁn. After
ﬁxation, nine parafﬁn 5 μm sections (three for each GLUT
isoform) were prepared for each of the examined placental
specimens. Parafﬁn-embedded sections were stained using
an IHC Select® HRP/DAB kit from Merck Millipore
(Darmstadt, Germany) and according to the protocol
recommended by the manufacturer. Brieﬂy, the slides were
deparafﬁnized using xylene and rehydrated with ethanol.
Preliminary antigen retrieval was achieved by high tem-
perature processing of the samples in citrate buffer (pH 6.0)
for 10 min. and endogenous peroxidase activity was quen-
ched by incubation of the sections with 3% H2O2 for
20 min. The sections were subsequently incubated with
blocking buffer (5% normal goat serum diluted in phos-
phate buffered saline, PBS), followed by overnight incu-
bation with primary antibodies at 4 °C. Respective primary
antibodies were used: (1) mouse monoclonal antibody to
GLUT-1 (NBP1-35926, Novus Biologicals, USA, dilution
1:200), (2) rabbit polyclonal antibody to GLUT-4 (ab654,
Abcam, USA, dilution 1:500), and (3) rabbit polyclonal
antibody to GLUT-9 targeting both GLUT-9a and GLUT-
9b variants (ab104623, dilution 1:1000). Following primary
incubation, the sections were washed and incubated with
horse radish peroxidase (HRP)-conjugated goat anti-mouse
(NB7539, 0.5% v/v) or goat anti-rabbit (ab97051, 0.5% v/v)
secondary IgG for 60 min. at room temperature. In order to
visualize the speciﬁcally bound anti-GLUT primary anti-
bodies, 3,3′-diaminobenzidine served as the chromogen for
HRP, which generates a brown to black-colored polymeric
oxidation product. Finally, the sections were counterstained
with hematoxylin, dehydrated and mounted. Assuming the
lack of cross-reactivity between pairs of GLUT isoforms
(less than 35% of identities between GLUT-4 vs. GLUT-9,
GLUT-1 vs. GLUT-4, and GLUT-1 vs. GLUT-9 using the
BLAST technique), the respective negative controls for
immunostainings were prepared simultaneously by repla-
cing anti-GLUT-1, anti-GLUT-4, and anti-GLUT-9 with
normal mouse or rabbit pre-immune IgG diluted with PBS
at the same protein concentration as that used for the pri-
mary antibodies. Immunostained sections were examined
and photographed using a Leica DMLB light microscope.
Mean density of placental microvessels
Considering the fact that some GLUT are expressed in
endothelial cells, it was presumed that the accuracy of
GLUT expression measurement in the placental tissue may
be inﬂuenced by the local differences in density of placental
microvessels. To minimize this discrepancy in the results,
identiﬁcation of the vascular elements in the placental sec-
tions was performed using endothelial cells marker—rabbit
polyclonal antibody against CD31 (ab28364, dilution 1:50).
The tissue was probed with the primary antibody for 30
min. Subsequently, a HRP-conjugated goat anti-rabbit
antibody was used as the secondary. Using light micro-
scopy with computed morphometry for quantitative analysis
(Quantimet 500C+ Image Processing and Analysis System,
Leica Cambridge Ltd., Cambridge, United Kingdom), the
vascular/extravascular tissular index (V/EVTI) was esti-
mated in the calibrated areas of the placental sections, as
described in detail elsewhere [22, 23]. Brieﬂy, each parafﬁn
section underwent three area analyses repeated by two
independent observers. To minimize bias, within the cali-
brated areas of the placental sections, analyzed visual ﬁelds
have been chosen randomly using the morphometric soft-
ware. The single area measured with the picture analyzer
amounted to 693287 μm2 and Table 1 provides the total
number of placental specimens, sections and visual ﬁelds
analyzed in the respective groups. The image analysis
procedure consisted in the measurement of the total vascular
area. Consequently, the total lumen area of all types of the
identiﬁed vessels was summed up in diabetic and non-
diabetic placentas. With the purpose of a minimizing dis-
ruption caused by technical errors, especially uniaxial sec-
tion of the vessel, the lowest value of the Ferret’s diameter
was accepted as the diameter of a single lumen. Thus, V/
EVTI represents the ratio which reﬂects the intensity of
vascularization and is most closely correlated with density
of placental microvessels.
Quantitative morphometric analysis of GLUT
expression
Following immunostainings, a quantitative immunohis-
tochemistry based on the morphometric software (Quanti-
met 500C+) was applied for GLUT-1, GLUT-4 and GLUT-
9 identiﬁcation in placental sections under light microscopy.
All morphometric procedures were carried out twice by
two independent researchers and the average values were
uploaded in the result recording tab. Intensity of immu-
nostaining was evaluated using mean color saturation
parameter and thresholding in grey-level histograms. Thus,
expression of the respective GLUT corresponded to the total
immunostained calibrated area of the examined sections,
where color saturation comprises segmentation-separation
criteria for the objects. A single analyzed image area
amounted to 134755 μm2 (magniﬁcation 400x). In order to
achieve a maximum accuracy of the measurements, the
following factors have been controlled or monitored: aver-
aging of image intake, hue, illumination, luminance, power
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supply, relation of illumination to quantiﬁcation of the area
percentage of the positively staining structures, shading
correction, and warming up. More detailed description of
these morphometric procedures was given previously else-
where [23]. During comparative measurements of GLUT
expression in placental tissue samples in the studied groups,
the vascular density-matched samples were analyzed. In any
case, the difference between median V/EVTI values did not
exceed ±5%.
Statistical analysis
Statistical analysis was performed using the R package
v.3.2.1 (The R Foundation for Statistical Computing,
Vienna, Austria). Continuous variables were compared
using the Kruskal–Wallis rank sum test with the post-hoc
Dunn’s test and for categorical variables the chi-square test
with the Bonferroni correction was applied. The results
were expressed as median and interquartile range (IQR), or
median of percentage values and IQR. The p-value of <0.05
was considered as statistically signiﬁcant.
To assess the inter and intra-observer agreement in
immunohistochemical images, interpretation kappa statistic
(ĸ) was used. The observer agreement was considered
almost perfect when ĸ value was above 0.80; a ĸ value of
0.61–0.80, substantial agreement; a ĸ value of 0.41–0.60,
moderate agreement; a ĸ value of 0.21–0.40, fair agree-
ment; and a ĸ value of less than 0.20 indicated poor
agreement.
Results
After the completion of data collection, 25 women in
uncomplicated pregnancy were assigned to the control
group, while 28 age-matched patients constituted the study
group comprising of 16 GDMG1, 6 GDMG2, and 6 PGDM
type 1 (2 White class B and 4 White class C) diabetics. The
characteristics of the patients from whom placental samples
were obtained are shown in Table 2. Statistically signiﬁcant
differences between the subgroups of patients with GDM
and non-diabetic controls were found in fasting glucose (p
< .05), as well as 1-h and 2-h plasma glucose concentrations
during OGTT (p< .01). With regard to the perinatal data,
the analysis revealed that both placental and fetal weights in
the diet-controlled GDM group were signiﬁcantly lower as
compared to other diabetic patients and with an uncompli-
cated pregnancy (p< .05). Fetal macrosomia proved to be
an additional, statistically signiﬁcant differentiation factor
between PGDM and diet-controlled GDM patients (p< .05),
and with a two-fold higher incidence as compared to con-
trols (p= .08). Mean third trimester concentrations of gly-
cated hemoglobin in the GDMG1, GDMG2 and PGDM
groups were 5.23± 0.34%, 5.87± 0.37% and 5.68±
0.66%, respectively (normal range: ≤6%).
Immunohistochemical techniques used for identiﬁcation
of GLUT-1, GLUT-4 and GLUT-9 revealed the presence of
all GLUT in the placental tissue (Fig. 1). Membrane
expression of the immunostained protein in the apical
region of the trophoblast, including the microvilli, corre-
sponded predominantly with the GLUT-1 isoform, while
Table 1 Summary of the















GDMG1 16 A: 16 48 × 3 48 × 3 48 × 3
B: 16 48 × 3 48 × 3 48 × 3
GDMG2 6 A: 6 18 × 3 18 × 3 18 × 3
B: 6 18 × 3 18 × 3 18 × 3
PGDM 6 A: 6 18 × 3 18 × 3 18 × 3
B: 6 18 × 3 18 × 3 18 × 3
Control 25 A: 25 75 × 3 75 × 3 75 × 3
B: 25 75 × 3 75 × 3 75 × 3
Total: 53 A: 53 159 × 3 159 × 3 159 × 3
B: 53 159 × 3 159 × 3 159 × 3
A + B= 106 A + B= 954 × 3= 2862 images
Specimens obtained from central (A) and peripheral (B) regions of the placenta in the respective groups of
diabetic patients (GDMG1 diet-controlled gestational diabetes mellitus, GDMG2 insulin-controlled
gestational diabetes mellitus, PGDM pregestational diabetes mellitus) and non-diabetic controls. Three
sections have been prepared from each placental specimen for each of the analyzed GLUT: GLUT-1, GLUT-
4, GLUT-9. Next, from each section a digital camera captured the images of three visual ﬁelds in the optical
system
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the expressions of both, GLUT-4 and GLUT-9 were more
blurry, shifted somewhat towards the cytoplasmic com-
partment of the trophoblast cells. None of the immunor-
eactions described above were observed when normal
mouse or rabbit pre-immune IgG were used (Fig. 1).
In both, the control and the study groups (except for
PGDM), median V/EVTI values were increased in the
specimens obtained from the peripheral region of the pla-
centa as compared to the specimens from the central part,
however the differences did not reach statistical signiﬁcance
(Fig. 2). As a result, further analyses of both V/EVTI and
the respective GLUTs expression were performed alto-
gether (specimens: A + B) within the diabetic and non-
diabetic groups. The analysis revealed median V/EVTI
values to be signiﬁcantly increased in the placentas from
PGDM patients as compared to the other groups (p< .05)
(Fig. 2).
The results of the quantitative morphometric analysis
performed for the vascular density-matched placental sam-
ples revealed that the intra-observer agreements were
superior to the inter-observer agreements and the ĸ values
for GLUT-1, GLUT-4, and GLUT-9 are summarized in
Fig. 3. A signiﬁcant increase in the expression of GLUT-4
and GLUT-9 in insulin-dependent diabetic patients
(GDMG2 + PGDM) as compared to both, control and
GDMG1 groups was noted, (p< .05; Fig. 4). Contrary to
the two above-mentioned isoforms, signiﬁcantly increased
GLUT-1 expression was observed only in placental speci-
mens from patients with PGDM (p< .05). No statistically
signiﬁcant differences in GLUT expression were found
between GDMG1 patients and healthy controls.
Discussion
The present study investigated the expression of GLUT,
GLUT-1, GLUT-4 and GLUT-9, in stained placental sec-
tions from physiological and diabetes-complicated preg-
nancies using computer-assisted quantitative morphometry.
To the best of our knowledge, this has been the ﬁrst study to
Table 2 Patient and pregnancy characteristics in diabetic and control populations
GDMG1 (n=16) GDMG2(n=6) PGDM (n=6) Control (n=25) p value
Age (years) 33 [30–37] 34 [29–37] 35 [33–36] 30 [28–32] .10
Gestational age (weeks) 39 [38–39] 39 [38–39] 37 [37–38] 39 [39–39] .07
Gravidity 2 [2–3] 2 [2–3] 1 [1–1] 2 [1–2] .11
Parity 2 [1–2] 2 [1–2] 1 [1–1] 2 [1–2] .13
Pre-pregnancy BMI (kg/m2) 25.9 [22.4–27.1] 23.2 [22.1–32.2] 22.1 [19.3–23.1] 22.6 [21.8–24.1] .14
Fasting plasma glucose (mg/dl)a 86 [80–97] 98 [96–112] – 79 [74–83] <.05*
1-h plasma glucose (mg/dl)a 181 [159–186] 162 [148–188] – 120 [102-144] <.01*
2-h plasma glucose (mg/dl)a 156 [138–163] 153 [143–158] – 103.5 [85.5–116.5] <.01*
Mode of delivery
Vaginal delivery 6 (37.5%) 0 0 9 (36.0%) .11
Cesarean section 10 (62.5%) 6 (100%) 6 (100%) 16 (64.0%)
Fetal weight (g) 3270 [3180–3430] 3550 [2980–4410] 4010 [3790–4080] 3470 [3240–3810] <.05†
Fetal sex
Male 9 (56.3%) 2 (33.3%) 5 (83.3%) 14 (56.0%) .63
Female 7 (43.7%) 4 (66.7%) 1 (16.7%) 11 (44.0%)
Fetal macrosomiab 0 2 (33.3%) 3 (50.0%) 5 (20.0%) <.01‡
Apgar score 10 [10–10] 10 [10–10] 10 [10–10] 10 [10–10] .96
Placental weight (g) 523 [457–677] 634 [472–683] 733 [700–796] 597 [498–664] <.05†
Fetal/ placental ratio 6.9 [5.1–7.2] 6.1 [5.3–7.1] 5.4 [5.4–5.6] 6.3 [5.5–6.7] .24
Data are expressed as median [IQR, interquartile range], or as frequency (%)
GDMG1 diet-controlled gestational diabetes mellitus, GDMG2 insulin-controlled gestational diabetes mellitus, PGDM pre-gestational diabetes
mellitus
*GDMG1, GDMG2 vs. control
†GDMG1 vs. GDMG2, PGDM, control
‡GDMG1 vs. PGDM
aresults of the 75 g OGTT performed between 24–28 gestational weeks
bfetal macrosomia deﬁned as birth-weight over 4000 g irrespective of gestational age
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Fig. 1 Immunohistochemical localization of GLUT in human term
placenta at 400x magniﬁcation: GLUT-1 (a); GLUT-4 (b); GLUT-9
(c). The respective negative controls (a’), (b’), and (c’) are also pre-
sented (magniﬁcation 100×). A single visual ﬁeld observed with the
naked eye looks substantially uniformly within each studied group.
For that reason, to avoid unjustiﬁed overloading with the pictures, only
one immunostaining is presented for GLUT-1, GLUT-4, and GLUT-9
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use the abovementioned method to evaluate the expression
of selected GLUT isoforms in human term placenta. The
results of immunohistochemical staining conﬁrmed the
presence of all GLUT proteins in the trophoblast from both,
uncomplicated and diabetic pregnancies. Additionally,
insulin therapy might be responsible for the increased pla-
cental expression of GLUT-4 and GLUT-9, and partially
GLUT-1, in women with GDMG2/PGDM.
GLUT-1 is the most common GLUT found in the human
placenta. Thus, it is believed to be the main isoform
responsible for glucose transfer into the fetal circulation by
the vast majority of researchers [1, 2, 4, 19]. In the
syncytium, GLUT-1 expression is asymmetric, with three-
fold higher density in the maternal-facing microvillous
membrane (MVM) as compared to the fetal-facing basal
membrane (BM) [2]. In the present study, transporter
expression was the most intense in the trophoblast mem-
branes, including microvilli, which is consistent with pre-
vious reports [1–5, 19]. Contrary to transporter localization,
attempts at quantitative analysis of GLUT-1 expression in
the placenta have so far failed to generate unambiguous
results. Studies using membrane fractions of the syncytium
either found no differences between transporter expression
in MVM and BM of GDM women and healthy controls, or
reported increased expression only in the BM fraction [14,
16]. On the other hand, recent use of unfractionated tro-
phoblast membranes has revealed a signiﬁcant increase of
the GLUT-1 expression only in insulin-controlled GDM
patients [17]. In the present study, morphometric analysis
demonstrated no differences in GLUT-1 expression
between GDM women and healthy controls, similarly to the
results of Jansson et al. [16]. The reasons for the dis-
crepancies between the remaining authors remains unclear.
However, the analysis of the GLUT-1 expression in sepa-
rate tissue fractions of the trophoblast, as well as different
diagnostic criteria and thresholds of glycemic control in
GDM patients, should be taken into consideration. In case
of PGDM women, results of the earlier studies demon-
strated higher GLUT-1 expression in syncytial BM, without
Fig. 3 Intra and inter-observer agreement calculated for each studied
GLUT isoform, measured with 95% conﬁdence interval. The observer
agreement was considered good (substantial to almost perfect) when
the ĸ value was above 0.60
Fig. 4 Expression of the respective glucose transporters (GLUT-1,
GLUT-2, GLUT-9) in placental sections: diabetes-complicated preg-
nancy (non-insulin-dependent [GDMG1—diet-controlled gestational
diabetes mellitus] and insulin-dependent [GDMG2—insulin-controlled
gestational diabetes mellitus; PGDM—pregestational diabetes melli-
tus]) vs. vascular density-matched non-diabetic controls. Median of the
percent values and IQR. The median value in the respective controls
was taken as 100%*. * The value of the median in all controls (GLUT-
1, N= 25; GLUT-4, N= 25; and GLUT-9, N= 25) have showed
strong coherence with the respective mean value and the differences
between the median and the mean under no circumstances did not
exceeded ±5%
Fig. 2 A comparative examination of microvessel density in the pla-
cental sections (A—central part, B—peripheral part of the placenta)
using the vascular/extravascular tissular index (V/EVTI); the median
values (abstract numbers) and IQR. GDMG1 diet-controlled gesta-
tional diabetes mellitus, GDMG2, insulin-controlled gestational dia-
betes mellitus, PGDM pregestational diabetes mellitus
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signiﬁcant differences with regard to MVM, which to some
extent conﬁrms the general increase in transporter density
observed in morphometry [14, 15].
We have demonstrated a signiﬁcant increase in the
GLUT-9 expression in the placental samples from GDMG2
and PGDM women, as well as lack of differences when
GDMG1 patients and healthy controls were compared.
Similar results were reported by the authors of the only
study, so far, to investigate the expression of two separate
GLUT-9 isoforms: GLUT-9a and GLUT-9b in membrane
fractions of the syncytiotrophoblast in diabetic placentas
[8]. As for GLUT-9a, the authors found signiﬁcantly
increased expression in syncytial BM from the diabetic
pregnancies, including GDMG1, whereas GLUT-9b was
predominant in MVM and BM only in GDMG2/PGDM
women. In light of the fact that the present study did not
analyze the expression of the individual GLUT-9 variants,
the results of Bibee et al., do not differ notably from our
quantitative morphometric ﬁndings. Taking into account the
main objectives, the results from both studies conﬁrmed that
GLUT-9 is involved in maternal-fetal hexose exchange, and
that trophoblastic expression of the transporter is sig-
niﬁcantly increased in diabetic women, especially during
insulin therapy. Importantly, the fact that GLUT-9 belongs
to class II of the facilitative transporter family is the reason
why its ability to transfer fructose, whose excess—as in the
case of glucose—may be detrimental to fetal development,
constitutes one of its most signiﬁcant properties. Patients
with diabetes are known to have elevated fructose levels in
the blood, and fructose concentrations in the umbilical cord
and fetal blood are higher as compared to maternal levels
[24, 25]. The latter may be both, a result of the endogenous
production of fructose by the fetal-placental unit in phy-
siological pregnancy using glucose as the substrate, or—as
was proven by animal studies—a response to excessive
maternal fructose intake [25, 26]. Vickers et al., who
administered fructose solution to pregnant rats in order to
provide 20% of the daily caloric intake from fructose,
reported maternal hyperinsulinemia and signiﬁcantly higher
birth weight in the offspring [26]. One of the possible
explanations might be an increased GLUT-9 expression in
the placenta, however studies on transplacental fructose
transport and its effect on the development of human fetus
are lacking and the only results are based on animal models.
In this respect, it should be noted that the expression of
other fructose transporters, including the primary GLUT-5,
has not been conﬁrmed in the placenta so far [11, 18].
Unlike the two mentioned GLUT, in the initial studies on
the presence of GLUT-4 in the placenta it was found to be
absent or barely detectable [1, 4, 6]. It was not until the
study by Xing et al., that presence of GLUT-4 protein was
ﬁnally conﬁrmed in stromal cells of the placental villi [7].
The trophoblastic expression of GLUT-4 in human term
placenta reported in our study is an important ﬁnding
regarding the possibilities of regulating transplacental glu-
cose transfer and the effect of insulin on the intensiﬁcation
of intrauterine fetal growth. It has been well-documented
that the expression of GLUT-4 in human tissues, e.g. adi-
pose tissue or muscles, is closely correlated with insulin
stimulation, whose receptors can be found, among others, in
the placental syncytium [11, 27, 28]. In the course of insulin
therapy, increased GLUT-4 expression in the trophoblast
may be observed in women with GDMG2/PGDM, as was
conﬁrmed by the results of quantitative morphometry.
Direct consequences might include increased glucose ﬂux
into the fetal circulation, intensiﬁed fetal growth and the
subsequent macrosomia, which in the present study was
more common in the insulin-dependent diabetic groups.
Nonetheless, the presented hypothesis ought to be treated
with caution, taking into account results of the studies
which found no or only transient stimulatory effect of
insulin on glucose transfer in human term placenta [19, 29–
31]. In addition, the ﬁndings of three different studies which
compared the expression of GLUT-4 with clinical data not
only found no differences but also detected a decrease in the
placental transporter expression in women with fetal mac-
rosomia and/or insulin-dependent diabetes [6, 7, 17]. One
must remember, however, that the number of insulin
receptors in the syncytium decreases as pregnancy pro-
gresses, and the abovementioned studies evaluated GLUT-4
expression only in the membrane fractions of the tropho-
blast, while the majority of transporter is found in the
intracellular compartment [11, 27].
The analysis of the subgroups revealed a signiﬁcantly
higher incidence of macrosomia among women with
PGDM as compared to diet-controlled GDM. Also, the rate
of macrosomia in the former group was two-fold higher as
compared to healthy controls. These ﬁndings are consistent
with the increased expression of GLUT-4 and GLUT-9
transporters, and also partly GLUT-1, in the placentas of
women with insulin-dependent diabetes. The lack of cases
of fetal overgrowth in the GDMG1 group in the present
study might be the result of strict dietary adherence, which
is conﬁrmed by normal values of third trimester glycated
hemoglobin concentrations, and similar expression of
GLUT isoforms as compared to healthy controls. On the
other hand, the fact that 20% of the fetuses born to healthy
mothers were macrosomic indicates that glucose transfer is
not the only determinant of fetal growth and/or that there are
differences in the mechanisms regulating glucose transfer in
diabetic placentas as compared to physiological pregnan-
cies. For example, in the ﬁrst case, the enhanced lipoprotein
lipase activity and expression of fatty acid binding proteins
in the placenta of diabetic women may account for the
excessive transfer of free fatty acids into the fetal circulation
and subsequent fetal overgrowth [32]. On the other hand,
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the latter assumption is supported by the study of Osmond
et al., who demonstrated a decreased uptake and transfer of
glucose in perfused placentas from diet-controlled GDM
women as compared to healthy controls and insulin-
controlled GDM women [31]. In light of the above-
mentioned data and our ﬁndings, it seems safe to conclude
that, in the initial stages of GDM, elevated levels of glucose
trigger processes which limit the transfer of glucose from
the maternal to fetal circulation without a signiﬁcant change
in the total number of transporters. Post-translational mod-
iﬁcation of the transporters, recently postulated by Acosta
et al., or their intracellular translocation within the tropho-
blast observed in vitro, are examples of such processes [9,
20]. As a result, the fetus is protected from the detrimental
effect of maternal hyperglycemia, and the consequent threat
of macrosomia. Adequate glycemic control is the necessary
prerequisite in maintaining that condition and if the insulin
therapy needs to be initiated, the protective mechanisms are
attenuated, leading to excessive transfer of glucose to the
fetus. The ﬁnding that glycated hemoglobin levels were
within the normal range in the majority of insulin-dependent
women in the peripartum period and fetal macrosomia still
occurred in 33–50% of them indicates that insulin may be
one of the main factors which promote increased GLUT
expression and fetal overgrowth even under strict glycemic
control.
Both the placental and the fetal weights in an uncom-
plicated pregnancy were signiﬁcantly higher compared to
the GDMG1 patients, which, as there were no differences in
GLUT expression, may suggest that it is the larger exchange
surface area of the placenta and consequently the larger total
number of transporters rather than their density that affects
the birthweight of the fetus [6, 9]. The above assumption
could be of importance, especially in cases of well-
controlled GDMG1 and, apart from the already speciﬁed
mechanisms, could provide further explanation of our
observations. In the case of GDMG2/PGDM patients, the
insulin may simultaneously stimulate placental growth and
increase in the expression of GLUT, leading to more
intensive fetal growth. However, as there are no studies
evaluating the correlation of GLUT expression with mea-
surements of the maternal surface area of the placenta, we
cannot deﬁnitely conﬁrm the hypothesis.
The present study is subject to some limitations; for
example, the fact that the method used assesses GLUT
expression in the membranes as well as in the cytosol of the
trophoblast, whereas only the former group is directly
responsible for glucose transfer, may be questioned. One
must remember, however, that the omission of the intra-
cellular GLUT fraction in the quantitative analysis may not
fully reﬂect the transport capacity of the trophoblast, par-
ticularly taking into account that this pool of transporters
undergoes increased translocation towards the cell
membranes in response to stimulating factors such as
insulin [28, 33]. Another limitation of the study concerns
the possible impact of the mode of delivery on GLUT
protein expression considering there were no vaginal
deliveries in the GDMG2/PGDM group. However, in the
light of the studies evaluating GLUT-1 expression in MVM
and BM of the syncytiotrophoblast, where no differences
were demonstrated in the transporter density between
vaginal deliveries and those by cesarean section, it seems
unlikely that these factors are interdependent [2, 34].
In conclusion, the present study demonstrated the pre-
sence of GLUT-1, GLUT-4 and GLUT-9 in human term
placenta, as well as an increased expression of GLUT in the
placentas from insulin-dependent diabetic pregnancies.
Also, the fact that macrosomia was more common in the
group of women with insulin-dependent diabetes conﬁrms
the earlier assumption that excess glucose transfer across
the placenta may be responsible for fetal overgrowth. Fur-
ther studies aiming to identify the factors responsible for the
increased number of GLUT transporters and the mechan-
isms which regulate transport of glucose in human diabetic
placenta are therefore necessary.
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